Csl Behring Sp. z o.o. (Poland)

Csl Behring Sp. z o.o. operates in Poland as part of the CSL Behring biopharmaceutical organization focused on discovering, developing and supplying innovative therapies, with portfolio emphasis on treatments for rare diseases and serious conditions. Business segments and products include biologic therapies and specialty medicines addressing immunodeficiencies and autoimmune diseases, congenital blood-clotting disorders, hereditary angioedema, and alpha-1 antitrypsin deficiency; the business positions its products as therapies that could not be produced in other ways and highlights tightly controlled, advanced manufacturing standards for biologics. Geographic scope centers on the Polish market with patient and stakeholder-facing activities supported by global CSL Behring capabilities and product development and manufacturing footprint. Key assets include the CSL Behring brand, specialized biologics know-how, regulated quality and safety systems, and a therapeutic focus aligned with immunology and hematology-related rare diseases. Strategic focus and positioning emphasize innovation in specialty/rare-disease therapy areas, high production and safety standards, and patient-oriented information and support around disease areas and treatment pathways.